HB1100/376982/1

BY: Health and Government Operations Committee

AMENDMENTS TO HOUSE BILL 1100
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in the sponsor line, strike "Delegate Pendergrass" and substitute "Delegates Pendergrass, Bagnall, Barron, Belcastro, Bhandari, Carr, Charles, Chisholm, Cullison, Hill, Johnson, Kelly, Kerr, Kipke, Krebs, R. Lewis, Morgan, Pena–Melnyk, Reilly, Rosenberg, Saab, Sample–Hughes, Szeliga, and K. Young"; in line 2, after "Advisor," insert "Reports,"; in line 12, after "circumstances;" insert "altering certain dates for certain reporting requirements;"; and in line 18, after "(e)(1)(i)" insert ", 21–2C–07, and 21–2C–08(a)".

On page 2, in line 5, after "Section" insert "5, 7, and".

AMENDMENT NO. 2

On page 3, in line 1, strike "**DEPARTMENT**" and substitute "**BOARD**"; after line 7, insert:

"21–2C–07.

On or before December 31, **[**2020**]** **2021**, the Board, in consultation with the Stakeholder Council, shall:

(1) Study:

(i) The entire pharmaceutical distribution and payment system in the State; and

(ii) Policy options being used in other states and countries to lower the list price of pharmaceuticals, including:

(Over)

1. Setting upper payment limits;

2. Using a reverse auction marketplace; and

3. Implementing a bulk purchasing process; and

(2) Report its findings and recommendations, including findings for each option studied under item (1)(ii) of this section and any legislation required to implement the recommendations, to the Senate Finance Committee and the House Health and Government Operations Committee in accordance with § 2–1257 of the State Government Article.

21–2C–08.

(a) On or before December 31, **[**2020**]** **2021**, the Board shall:

(1) Collect and review publicly available information regarding prescription drug product manufacturers, health insurance carriers, health maintenance organizations, managed care organizations, wholesale distributors, and pharmacy benefits managers; and

(2) (i) Identify states that require reporting on the cost of prescription drug products; and

(ii) Initiate a process of entering into memoranda of understanding with the states identified under item (i) of this item to aid in the collection of transparency data for prescription drug products.".

On page 4, after line 12, insert:

"SECTION 5. AND BE IT FURTHER ENACTED, That, on or before June 1, **[**2020**]** **2022**, the Prescription Drug Affordability Board shall:

(1) conduct a study of the operation of the generic drug market in the United States that includes a review of physician–administered drugs and considers:

(i) the prices of generic drugs on a year–over–year basis;

(ii) the degree to which generic drug prices affect yearly insurance premium changes;

(iii) annual changes in insurance cost–sharing for generic drugs;

(iv) the potential for and history of drug shortages;

(v) the degree to which generic drug prices affect yearly State Medicaid spending; and

(vi) any other relevant study questions; and

(2) report its findings to the General Assembly, in accordance with § 2–1246 of the State Government Article.

SECTION 7. AND BE IT FURTHER ENACTED, That, on or before December 1, **[**2020**]** **2021**, the State Designated Health Information Exchange and the Prescription Drug Affordability Board established under § 21–2C–02 of the Health – General Article, as enacted by Section 1 of this Act, jointly shall:

(1) study how the Information Exchange can provide de–identified provider and patient data to the Board; and

(2) report their findings and recommendations, including any necessary statutory changes, to the General Assembly, in accordance with § 2–1246 of the State Government Article. ".